Webcast - Hepatitis C: where are we now? The landscape

The Viral Hepatitis Congress 2015

Last month researchers and physicians gathered at "The Viral Hepatitis Congress 2015" held in Kap Europa, Frankfurt, Germany to discuss new data on the changing treatment landscapes in both hepatitis B and hepatitis C. Other important topics included HIV co-infection, advances in managing HCC, to name a few.

Anyone living with HCV or considering treatment may be interested in viewing a webcast of the scientific program over at "ViralHepatitisTV." Abstracts from this meeting are published online in the "Journal of Viral Hepatitis."

The webcast is still in the process of being uploaded, links are provided below. 

The Viral Congress Sept 10-12

Welcome and introduction
Ira Jacobson, New York, US and Stefan Zeuzem, Frankfurt, Germany - Click here to view

Hepatitis C: where are we now? The landscape
US vs. EU: differences in the labels and guidelines for anti-HCV regimens
Nezam Afdhal, Boston, US – Click here to view

Hepatitis C:where are we now? The landscape - Q&A and panel discussion – Click here to view

Keynote lecture
HCV registries: what have we learned beyond the phase III trials?
David Nelson, Gainsville, US – Click here to view

Which DAA regimen should include ribavirin?
Graham Foster, London, UK – Click here to view

Drug–drug interactions: what remains relevant in HCV treatment?
David Back, Liverpool, UK – Click here to view

New data from latest clinical trials
Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C
Gamal Esmat, Cairo, Egypt – Click here to view

Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir ± ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study)Robert Flisiak, Bialystok, Poland – Click here to view

Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a compassionate use program
Tania Welzel, Frankfurt, Germany – Click here to view

Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial Didier Samuel, Villejuif, France – Click here to view

HCV-infected patients with renal and/or hepatic impairment and post-transplant
Treatment of patients with pre-terminal and terminal renal insufficiency
Paul Martin, Miami, US – Click here to view

Treatment of patients with decompensated liver cirrhosis: who benefits, who deteriorates, where is the point of no return?
Marc Bourlière, Marseille, France – Click here to view

Anti-viral management post-liver transplantation
Paul Kwo, Indianapolis, US – Click here to view

Scientific Posters
You can view the posters now as downloadable PDFs or as interactive, page-turning books, these files (which open in a new window) require the latest version of Flash Player to be viewed.

Book 1
Interactive Book or PDF
ORAL PRESENTATIONS
HEPATITIS C VIRUS – DIAGNOSIS (P1–P3)
HEPATITIS C VIRUS – NATURAL HISTORY AND EPIDEMIOLOGY (P5–P7)
HEPATITIS C VIRUS – TREATMENT AND LATE-STAGE CLINICAL TRIALS (P8-P10)

Book 2
Interactive Book or PDF
HEPATITIS C VIRUS – PRACTICAL MANAGEMENT STRATEGIES (P11)
HEPATITIS C VIRUS – TREATMENT MONITORING AND PREDICTORS OF THERAPEUTIC RESPONSE (P13–P16)
HEPATITIS C VIRUS – DIRECT-ACTING ANTIVIRAL COMBINATIONS (P17-P20)
HEPATITIS C VIRUS – MOLECULAR BIOLOGY AND CHARACTERISATION (P21–P22)

Book 3
Interactive Book or PDF
HEPATITIS C VIRUS – OTHER (P24–P25)
HEPATITIS B VIRUS – DIAGNOSIS AND MONITORING (P28-P29)
HEPATITIS B VIRUS – PRACTICAL MANAGEMENT STRATEGIES (P32)
HEPATITIS B VIRUS – MOLECULAR BIOLOGY AND CHARACTERISATION (P33–P43)
HEPATITIS B VIRUS – OTHER (P44)
HEPATOCELLULAR CARCINOMA (HCC) (P45)
TRANSPLANTATION AND VIRAL HEPATITIS (P47–P48)

Source - http://viral-hep.org/congress/